Actavis And Valeant Now Squaring Off For IBS Patients
This article was originally published in The Pink Sheet Daily
Viberzi and Xifaxan share an indication and an approval date, but not much else.
You may also be interested in...
Valeant Backs Strategy With Solid Deal Record
Reiterating the strength of its M&A-heavy strategy, Valeant CEO Michael Pearson touted the company's deal record during its second quarter earnings call.
Keeping Track: New Drugs For IBS, LAM; New NDAs for HCV and Hyperkalemia
The latest drug development news and highlights from our FDA Performance Tracker.
Capital Allocation In The Age Of Shareholder Activism
Maybe no company is safe from activists, but there are protective measures that managers and boards can take. What biopharmas can learn from Valeant Pharmaceuticals and Pershing Square’s pursuit of Allergan.